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Abstract
Introduction
Working adults spend much time at the workplace, an ideal set-
ting for wellness programs targeting weight loss and disease pre-
vention.  Few randomized trials  have evaluated the efficacy of
worksite diabetes prevention programs. This study evaluated the
efficacy of a worksite lifestyle intervention on metabolic and be-
havioral risk factors compared with usual care.
Methods
A pretest–posttest control group design with 3-month follow-up
was used. Participants with prediabetes were recruited from a uni-
versity worksite and randomized to receive a 16-week lifestyle in-
tervention (n = 35) or usual care (n = 34). Participants were evalu-
ated at baseline, postintervention, and 3-month follow-up. Dietary
intake was measured by a food frequency questionnaire and level
of physical activity by accelerometers. Repeated measures analys-
is  of  variance compared the  change in  outcomes between and
within groups.
Results
Mean (standard error [SE]) weight loss was greater in the inter-
vention (−5.5% [0.6%]) than in the control (−0.4% [0.5%]) group
(P < .001) postintervention and was sustained at 3-month follow-
up (P < .001). Mean (SE) reductions in fasting glucose were great-
er in the intervention (−8.6 [1.6] mg/dL) than in the control (−3.7
[1.6] mg/dL) group (P = .02) postintervention; both groups had
significant glucose reductions at 3-month follow-up (P < .001). In
the intervention group, the intake of total energy and the percent-
age of energy from all fats, saturated fats, and trans fats decreased,
and the intake of dietary fiber increased (all P < .01) postinterven-
tion.
Conclusion
The worksite intervention improved metabolic and behavioral risk
factors among employees with prediabetes. The long-term impact
on diabetes prevention and program sustainability warrant further
investigation.
Introduction
The prevalence of prediabetes among US adults increased signific-
antly  from  30.2%  in  1999–2002  to  36.5%  in  2007–2010  (1).
People with prediabetes are at increased risk for type 2 diabetes
mellitus (hereinafter referred to as type 2 diabetes) as well as mi-
crovascular and macrovascular comorbidities commonly associ-
ated with type 2 diabetes (2). Rising rates of prediabetes create an
urgent need to prevent or delay the development of type 2 dia-
betes.
Intensive lifestyle interventions can prevent or delay type 2 dia-
betes  in  at-risk  populations  (3–5).  These  interventions  target
weight loss by improving dietary patterns and increasing physical
activity (PA). The Diabetes Prevention Program (DPP), for ex-
ample, demonstrated that weight loss through lifestyle modifica-
tion was more effective than pharmacotherapy in reducing the in-
cidence of type 2 diabetes among adults with prediabetes, and the
relative  reduction in  incidence remained at  10-year  follow-up
(3,6). The current need is to translate effective interventions into
practice settings.
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Adults spend a large portion of their time at work, making the
workplace a potentially effective setting for health promotion and
disease prevention. Wellness programs can generate savings in
medical costs and reduce absenteeism rates. Although worksite
programs can promote weight loss (7), limited evidence exists on
worksite diabetes prevention programs for employees at high risk
of  diabetes.  The  workplace  could  be  an  opportune  setting  for
identifying employees with prediabetes, reducing risk through ef-
fective programs, and if employees avert type 2 diabetes, also re-
ducing future costs (8).
The  DPP  has  been  adapted  for  community  settings  such  as
churches, hospitals, and YMCAs (9). Although the community-
based programs promoted weight loss, thereby reducing risk for
type 2 diabetes (3,6), few translational studies have evaluated the
efficacy  of  worksite  diabetes  prevention  programs  (10–13).
Among worksite studies that implemented the DPP, only 2 studies
used a randomized design with a comparison condition (10,13), 2
studies reported the impact of the intervention on outcomes such
as glucose and lipid levels (10,12), and none reported changes in
dietary intake or objectively measured PA. Moreover, one works-
ite study implemented a primarily self-directed, low-intensity ver-
sion of the DPP (13), limiting comparability; in addition, study at-
trition was high (11,13). The objective of our trial was to evaluate
the efficacy of a worksite lifestyle intervention among employees
with prediabetes. It was hypothesized that the intervention would
facilitate greater reductions in the percentage of weight loss than
would usual care.
Methods
Design
A randomized pretest–posttest control group design was used at a
major university in the midwestern United States. Approval for the
study  was  obtained  from the  university’s  institutional  review
board, and all participants provided written, informed consent. Eli-
gible participants were randomized at baseline to either a 16-week
group-based lifestyle intervention or usual care from their health
care providers (control condition) (Figure). Beginning in October
2012, participants were enrolled and allocated to treatment group
in a 1-to-1 ratio by the project coordinator. Participants were ran-
domized in blocks of 4 stratified by race and sex; 2 participants
each were randomly assigned to the intervention or control arm.
Assignment was generated by the statistician, and allocations were
concealed in sequentially numbered opaque envelopes. The statist-
ician was blinded to treatment assignment; however, neither parti-
cipants nor lifestyle coaches were blinded to treatment allocation.
All  study  appointments  took  place  on  the  university  campus.
Postintervention data were collected after the 16-week interven-
tion, followed by a 3-month maintenance period, during which
participants received no contact from program staff;  final data
were collected 7 months after  enrollment.  Follow-up of  parti-
cipants was completed in May 2014 at trial end.
Figure. Phases of the randomized controlled trial  for the intervention and
usual care (control) groups in a university worksite diabetes prevention study,
Ohio, 2012–2014.
 
Sample
Potentially eligible participants with random glucose levels of 110
to 199 mg/dL during an annual employee health screening re-
ceived a letter from the university health plan inviting them to par-
ticipate. Additional study recruitment methods included campus
flyers, electronic advertisements in digital newsletters, employee
email notifications, and notices in ResearchMatch.com, a website
for study recruitment.
Eligibility criteria included being an employee aged 18 to 65 and
having a body mass index (BMI) of 25.0 to 50.0 kg/m2 and predia-
betes. The 7-item American Diabetes Association risk assessment
questionnaire was administered to determine risk for type 2 dia-
betes, and those with a score of 5 or more were classified as poten-
tially eligible and screened for any exclusionary criteria (14). Eli-
gible participants had fasting finger-stick glucose levels of 100 to
125 mg/dL, indicative of prediabetes (15). Individuals with fast-
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ing glucose levels of 95 to 99 mg/dL or 126 to 140 mg/dL com-
pleted a second finger stick to assess hemoglobin A1c (HbA1c);
HbA1c levels of 5.7% to 6.4% indicated prediabetes and study eli-
gibility (15). Individuals with HbA1c or glucose levels above the
indicated ranges were advised to see their physician and excluded
from participation.
Potentially eligible participants completed the Physical Activity
Readiness Questionnaire; those who answered positively to 1 or
more questions were excluded (16). Employees older than 65 re-
ceive a separate health plan through the state’s public employee
retirement system; they do not routinely complete the biometric
screening used for recruitment and were excluded from partici-
pation. Individuals were excluded if they had a current diagnosis
of type 2 diabetes, were pursuing or recently had weight-loss sur-
gery, were taking medications that modify blood glucose levels,
such as metformin or corticosteroids, or were actively participat-
ing in a weight-management program. Participants could not be
pregnant, breastfeeding, trying to become pregnant, or planning to
leave university employment or move from the area within one
year of study enrollment.
Lifestyle intervention
Participants randomized to the intervention group received the
manualized 16-week group-based intervention adapted from the
DPP Outcomes Study Lifestyle Balance Program (17,18). The be-
havioral goals for the program were consistent with those of the
DPP:  achieve  at  least  7% weight  loss,  engage  in  at  least  150
minutes per week of moderate to vigorous PA, and consume 25%
or less of total energy from fat (3). The intervention focused on a
lower-fat diet, and evidence suggests that reduced-calorie diets can
produce clinically meaningful weight loss (19). Groups of 10 to15
participants met for 60 minutes weekly during the lunch hour or
after work. Participants were encouraged to attend make-up ses-
sions and obtain a weight measurement if they missed a session.
Two university dietitians trained in intervention implementation
served as lifestyle coaches for the weekly sessions. Written study
materials, a book for estimating fat grams and calorie intake, and
booklets for self-monitoring diet and PA were provided to parti-
cipants.  Participants  received  individual  behavioral  goals  on
weight, fat-gram intake, and PA during the first session, and they
were encouraged to set small goals each week to facilitate pro-
gressive goal attainment. Participants engaged in group discus-
sions and completed individual and group activities to foster skill
development and social support. Participants were encouraged to
self-monitor diet and PA daily and to submit monitoring booklets
weekly for review by the lifestyle coach, who provided individual-
ized feedback.
Participants in the control group received usual care from their
health care providers.  At  baseline they received a  booklet  de-
veloped by the National  Diabetes  Education Program that  de-
scribes strategies for self-regulated weight loss (20). Use of these
materials is associated with modest weight loss (21). In their writ-
ten materials, the control group was given a 7% target for weight
loss. Following completion of all data collection, control group
participants were invited to attend an informational session that
addressed key weight-loss principles from the intervention.
A checklist for monitoring adherence to the intervention program
was used to ensure fidelity. The principal investigator observed
more than 20% of intervention sessions and found no serious de-
partures from the curriculum as planned.
Measures
All study measures were collected at baseline, postintervention (4
months), and at 3-month follow-up (7 months). The primary out-
come was percentage weight change; secondary outcomes were
anthropometric measures (height, waist circumference), clinical
measures (glucose, blood lipids, blood pressure), dietary intake,
and PA levels. Body weight was measured using a calibrated digit-
al scale (Health-O-Meter Professional). Height was measured at
baseline using a standing stadiometer (Perspective Enterprises).
For  height  and  weight  measurements,  participants  wore  light
clothing and removed shoes. Waist circumference was assessed
using the National Health and Nutrition Examination Survey pro-
tocol (22). Anthropometric measurements were collected twice per
visit, and mean values were used for analyses.
Finger-stick blood samples were collected after a minimum 8-hour
fast. The Alere Cholestech LDX System (23) was used to com-
plete point-of-care analysis of the blood samples for glucose, total
cholesterol,  high-density  lipoprotein  (HDL)  cholesterol,  and
triglycerides. Low-density lipoprotein (LDL) cholesterol was cal-
culated using the Friedewald equation (24). The Alere Cholestech
LDX System was certified as accurate and reproducible by the
Centers for Disease Control and Prevention’s Lipid Standardiza-
tion Program and Cholesterol Reference Method Laboratory Net-
work (23). At each assessment, 2 systolic and 2 diastolic blood
pressure readings were collected from seated participants with an
Omron  Healthcare  7-Series  home  blood  pressure  cuff,  which
meets the protocol criteria for validation standards of the European
Society of Hypertension (25).
Dietary  intake  was  estimated  from the  self-administered  full-
length Block 2005 Food Frequency Questionnaire (FFQ) (Nutri-
tionQuest). Portion sizes ranged from ¼ cup to 2 cups, and a food
portion visual aid was provided. Nine response options on fre-
quency of intake were included. PA was assessed using the Life-
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corder Plus Accelerometer (Suzuken-Kenz, Inc), which estimates
minutes spent in light, moderate, and vigorous PA. Participants
were instructed to wear the accelerometer on their hip at the waist-
line for all waking hours on 7 consecutive days during each as-
sessment.
Analysis
Between-group differences in baseline demographic characterist-
ics were assessed using Pearson χ2 tests or Fisher exact tests; dif-
ferences in age were assessed using a 2-sample t  test.  We de-
veloped and validated mixed models in which participants nested
within treatment groups were used as random effects, and treat-
ment group, time, and their interaction were used as fixed effects.
Outcome variables were assessed in the framework of these mod-
els using Student t tests within a repeated measures analysis of
variance framework for between-group comparisons of mean val-
ues at baseline, and between-group and within-group change from
baseline to postintervention and from baseline to 3-month follow-
up. Outcome variables with residuals containing skewed distribu-
tions were modeled on the logarithmic scale to achieve approxim-
ately normal distributions. Relationships between postintervention
weight change and intervention participation were assessed using
Spearman correlations. Power analysis (power = 0.90, 2-tailed α =
.05) for the primary outcome, percentage weight change, based on
a previous DPP translational study, indicated that 25 participants
in each treatment group were needed to detect a 4.04% difference
between groups (21).  All  analyses were completed using SAS
software package JMP version 10 (SAS Institute, Inc).
Results
We found no significant differences in demographic characterist-
ics between eligible individuals who enrolled in the study and
those who declined enrollment, except for age (50.6 vs. 44.9 years,
respectively; P = .005). We found no significant baseline differ-
ences in demographic characteristics between treatment groups,
except for occupation (P = .01) (Table 1). Similarly, we found no
significant difference between treatment groups at baseline for
study outcomes,  except  for  significantly lower diastolic blood
pressure in the control than intervention group (P = .04) (Table 2).
We found no significant differences in participant characteristics
at baseline between those who did and those who did not com-
plete the study (all P > .05).
We found a significant between-group difference in mean (SE)
percentage  weight  change  from  baseline  to  postintervention
(−5.5%  [0.6],  intervention;  −0.4%  [0.5],  control;  P  <  .001).
Postintervention, the intervention group achieved significantly
greater reductions in waist circumference, fasting glucose, and
systolic and diastolic blood pressure than did the control group (all
P < .025). Total cholesterol declined significantly (P = .01) in the
intervention group.
The intervention group had a greater reduction in percentage en-
ergy from fat (P = .008) and a greater increase in fiber intake (P =
.05) than the control group. In the intervention group postinterven-
tion, total energy intake decreased significantly (P < .001); intake
of total fats, saturated fats, and trans fats decreased significantly;
and carbohydrate and dietary fiber intake increased significantly
(all P < .01).
Changes from baseline to 3-month follow-up remained signific-
antly greater for the intervention than the control group for per-
centage weight change, body weight, waist circumference, and
systolic and diastolic blood pressure (all P < .05). HDL cholester-
ol significantly increased from baseline to 3-month follow-up (P =
.002) in the intervention group; this increase was significantly dif-
ferent from that of the control group (P = .04).
Changes in dietary intake and PA from baseline to 3-month fol-
low-up were not significantly different between groups for any
outcome.  Total  energy  intake  significantly  decreased  from
baseline in the intervention group (P = .002) and control group (P
< .001) at study end.
In the intervention group, 32.4% met the goal of achieving 7% or
more weight loss postintervention, which was significantly more
than in the control group (2.9%; P = .003). The proportion of parti-
cipants  in  each  group who lost  more  than  5% of  their  weight
differed postintervention and at  3-month follow-up (Table  3).
Fewer than 10% of participants in either group met the dietary
goal of consuming 25% or less of total energy intake from fat at
any time point. Postintervention, although few participants met the
behavioral goal, fat intake had shifted from baseline more in the
intervention than in the control group (P = .01).
The mean (standard deviation [SD]) number of sessions attended
by intervention participants was 11.6 (4.5) or 72.5% of the 16 ses-
sions offered. Participants recorded their dietary intake for a mean
(SD) of 5.6 (1.5) days per week, and reported a mean (SD) of
161.9 (135.0) minutes per week of PA. In the intervention group,
the change in body weight postintervention was negatively associ-
ated with total days of self-monitoring dietary intake (r = −0.62, P
< .001), total minutes spent in PA (r = −0.49, P = .004), and total
number of sessions attended (r = −0.60, P < .001).
Discussion
The 16-week group-based lifestyle intervention delivered at a uni-
versity worksite facilitated reductions in body weight among em-
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ployees with prediabetes. These results support the efficacy of the
intervention for promoting risk reduction (3) and provide evid-
ence for its utility at the worksite. Whereas 50% of participants
who received the original 24-week DPP intervention, which in-
cluded individual counseling, lost at least 7% of body weight (3),
32.4% of intervention participants in our study lost that amount.
The smaller proportion in our study may have resulted from the
shorter intervention period and group delivery format. We chose a
group delivery format for a worksite approach to reduce person-
nel demands and enhance employee cohesion and support.
Weight loss in the DPP was the primary predictor of reduction in
diabetes incidence; every percentage point of weight loss achieved
at the end of the intervention contributed to a 10% reduction in
diabetes  risk,  independent  of  glycemic  changes  (26).  Mean
postintervention weight loss in our study was 5.5%, which is con-
sidered clinically significant and is frequently associated with re-
duced morbidity and mortality (27). An 8-year longitudinal study
examined changes in risk factors after a worksite wellness pro-
gram at a US university and found that obese participants who
achieved and maintained a BMI less than 30 kg/m2 for 3 consecut-
ive years reduced the risk of developing type 2 diabetes by 78%
compared with those who remained obese (28).  Thus,  a  mean
weight loss of 5.5% following the intervention in our study con-
tributes to risk reduction for type 2 diabetes. Long-term follow-up
is needed to determine the progression to type 2 diabetes after
weight loss.
Fasting glucose values returned to near-normal levels in the inter-
vention group postintervention, and the improvement was main-
tained at 3-month follow-up. Each 5 mg/dL decrement of fasting
glucose at 6 months in the DPP was related to a 26% reduction in
diabetes risk (26). We did not assess postload glucose. DPP re-
ports identified the lifestyle intervention as being superior to met-
formin in restoring normal postload glucose values; however, that
was not the case for fasting glucose (3). Further research of works-
ite translations of the DPP should consider assessing both fasting
and postload glucose; however, the assessment of postload gluc-
ose increases participant burden and study costs.
PA levels in the intervention group approached the goal of 150
minutes per week postintervention. However, PA returned to near
baseline levels after the 3-month maintenance phase. Half of the
intervention group achieved the PA goal postintervention, suggest-
ing that this population of primarily working women struggled to
initiate and sustain regular PA. The postintervention decline in PA
is consistent with findings from other lifestyle interventions docu-
menting that overweight individuals with or at risk for chronic dis-
ease often rapidly return to sedentary behavior upon intervention
completion (29). However, our findings are in contrast to the DPP,
in which 74% of lifestyle participants met the goal immediately
after  intervention completion,  and 67% did 2 years  later  (30).
Working adults may need more support than the general popula-
tion to increase PA levels. Incentives used in the DPP to keep par-
ticipants at goal may have been responsible for the higher levels of
PA observed (18). Free-of-charge membership to campus exercise
facilities might enhance engagement in PA for university worksite
studies. A meta-analysis of PA interventions concluded that to be
most effective, interventions targeting PA should include self-
monitoring, goal setting, and modeling PA behaviors (31). Al-
though our intervention included both PA self-monitoring and
goal setting, the findings suggest that greater emphasis on the de-
velopment and practice of key PA-related self-regulatory skills (ie,
goal setting, barrier problem solving, PA planning) necessary to
facilitate the transition to independent maintenance of PA may
also promote long-term PA adherence.
Study participants reported changes in dietary intake. Total en-
ergy intake and percentage energy from fat decreased and fiber in-
take increased significantly in the intervention group postinterven-
tion. Lower fat intake and greater fiber intake in combination with
modest weight loss and increased PA was associated with reduced
risk for type 2 diabetes among at-risk adults (32,33). Reducing fat
intake to less than 30% of energy is associated with preventing
weight regain after periods of energy restriction, highlighting the
benefits of reduced fat intake for long-term maintenance of weight
loss (34).
Energy intake at 3-month follow-up also decreased significantly
(P < .001) in the control group. All eligible participants were in-
formed after screening that their glucose values were in the predia-
betes range, and the control group received written materials on
diet and PA changes to promote weight loss. Knowledge of their
own prediabetes may promote behavioral change in at-risk indi-
viduals.  Additionally,  participants may have reported lifestyle
changes because of repeated assessment of weight, diet, and PA
behaviors, consistent with the Hawthorne effect.
Although results from our study are promising, some limitations
exist. Follow-up was limited to 3-months postintervention; thus,
long-term outcomes are unknown. A larger translational study
with longer follow-up is needed to further evaluate effectiveness
in delaying or preventing type 2 diabetes. A worksite approach is
promising for tracking disease progression, especially when annu-
al employee biometric screenings are implemented. For worksite
adoption, the lifestyle intervention needs to be cost-effective, sus-
tainable, and compatible with existing health care systems. Future
research should evaluate the cost-effectiveness and long-term sus-
tainability of worksite translations of the DPP. In our study, 80%
of the participants were women, whereas 62% of the benefit-eli-
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gible university employees were women. Disparity in enrollment
by sex is common in weight-loss studies, and recruitment of men
deserves further evaluation. Men may benefit from Internet-based
gender-tailored programs (35).  Future research should address
how best to tailor programs to the interests and needs of men and
racial/ethnic minority populations.
Prediabetes is a growing problem in the United States and places
individuals at increased risk for type 2 diabetes. Worksites can be
effective settings for offering health promotion programs to em-
ployees; however, few studies have evaluated the impact of the
DPP intervention at the worksite. Our study contributes to the lim-
ited evidence and demonstrates, through a randomized design, the
feasibility and efficacy of the group-based DPP intervention in fa-
cilitating improvement in lifestyle behaviors, weight control, and
reduction in metabolic risk for type 2 diabetes among university
employees with prediabetes.
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Tables
Table 1. Demographic Characteristics of Participants in a Diabetes Prevention Study at a University Worksite, by Treatment Group
at Baseline, 2012–2014a
Characteristic Intervention (n = 35) Control (n = 34) P Value
Age, mean (SD), y 51.6 (9.5) 51.0 (8.1) .50b
Race
White 27 (77.1) 30 (88.2)
.34c
Asian or black 8 (22.9) 4 (11.8)
Ethnicity
Non-Hispanic 35 (100.0) 33 (97.1)
.49c
Hispanic 0 1 (2.9)
Sex
Male 7 (20.0) 7 (20.6)
>.99c
Female 28 (80.0) 27 (79.4)
Education
Less than bachelor’s degree 15 (42.9) 9 (26.5)
.32dBachelor’s degree 11 (31.4) 12 (35.3)
Postgraduate degree 9 (25.7) 13 (38.2)
Employment status
Full-time employment 32 (91.4) 33 (97.1)
.61c
Part-time employment 3 (8.6) 1 (2.9)
Marital status
Married 24 (68.6) 26 (76.5)
.59c
Not married 11 (31.4) 8 (23.5)
Occupation typee
Professional 12 (35.3) 19 (55.9)
.01dClerical 10 (29.4) 13 (38.2)
Other 12 (35.3) 2 (5.9)
Years at current job
1–5 13 (37.1) 11 (32.4)
.27d
6–10 13 (37.1) 7 (20.6)
11–15 3 (8.6) 6 (17.7)
≥16 6 (17.1) 10 (29.4)
a Values are number (percentage) unless otherwise indicated.
b Two-sample t test of between-group difference; P value < .05 was used for significance.
c Fisher exact test of between-group differences; P value < .05 was used for significance.
d Pearson χ2 test of between-group differences; P value < .05 was used for significance.
e One participant in intervention group did not provide this information.
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(continued)
Table 1. Demographic Characteristics of Participants in a Diabetes Prevention Study at a University Worksite, by Treatment Group
at Baseline, 2012–2014a
Characteristic Intervention (n = 35) Control (n = 34) P Value
Student status
Nonstudent 30 (85.7) 32 (94.1)
.22dFull-time student 3 (8.6) 0
Part-time student 2 (5.7) 2 (5.9)
Number of people in the household
1 5 (14.3) 2 (5.9)
.64d
2 17 (48.6) 16 (47.1)
3 6 (17.1) 5 (14.7)
4 5 (14.3) 9 (26.5)
≥5 2 (5.7) 2 (5.9)
Annual household incomee, $
20,000–39,999 8 (23.5) 3 (8.8)
.22d
40,000–59,999 4 (11.8) 4 (11.8)
60,000–79,999 6 (17.7) 6 (17.6)
80,000–99,999 9 (26.5) 6 (17.6)
≥100,000 7 (20.6) 15 (44.1)
a Values are number (percentage) unless otherwise indicated.
b Two-sample t test of between-group difference; P value < .05 was used for significance.
c Fisher exact test of between-group differences; P value < .05 was used for significance.
d Pearson χ2 test of between-group differences; P value < .05 was used for significance.
e One participant in intervention group did not provide this information.
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Table 2. Changes in Anthropometric, Clinical, Dietary, and Physical Activity Outcomes of Participants in a Diabetes Prevention
Study at a University Worksite, by Treatment Group at Baseline, 4 Months, and 7 Months, 2012–2014
Outcome
ANOVA Model Effects
Timea
Intervention, Mean (SE)
(n = 35)b
Control, Mean
(SE) (n = 34)b P ValuecTime Group Group × Time
Weight change, %d  —  —  —
Baseline  —  —  —
4 Months −5.5 (0.6) −0.4 (0.5) <.001
P value <.001 .81 —
7 Months −5.2 (1.0) −0.2 (0.7) <.001
P value <.001 .80 —
Body weight, kg <.001 .02 <.001
Baseline 95.4 (2.9) 101.9 (2.9) .12
4 Months −5.1 (0.6) −0.4 (0.6) <.001
P value <.001e .56 —
7 Months −4.9 (0.6) −0.4 (0.6) <.001
P value <.001 .58 —
Body mass index, kg/m2 <.001 .15 <.001
Baseline 35.0 (1.0) 35.9 (1.0) .53
4 Months −1.9 (0.2) −0.1 (0.2) <.001
P value <.001 .63 —
7 Months −1.7 (0.2) −0.1 (0.2) <.001
P value <.001 .76 —
Waist circumference, cm <.001 .04 .01
Baseline 107.2 (2.0) 110.8 (2.0) .21
4 Months −4.8 (0.9) −1.3 (0.9) .007
P value <.001 .15 —
7 Months −5.1 (0.9) −2.1 (0.9) .02
P value <.001 .02e —
Fasting glucose, mg/dL <.001 .11 .05
Baseline 108.9 (1.8) 110.8 (1.9) .52f
4 Months −8.6 (1.6) −3.7 (1.6) .02f
P value <.001 .02 —
7 Months −8.2 (1.5) −7.5 (1.6) .69f
P value <.001 <.001 —
Abbreviations: ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a Analyses conducted at baseline, change from baseline to postintervention (4 months), and change from baseline to 3-month follow-up (7 months).
b One participant in intervention group did not complete 4-month data collection, and 1 participant in control group did not complete 7-month data collection.
c Posthoc t test in a repeated measures ANOVA model for between-group comparison at baseline and to compare between-group change from baseline to 4 and 7
months; P value <.05 was used for significance.
d Analyses for primary outcome included student t test for within-group difference from 0 for the change at 4 and 7 months in intervention group; data were not
normally distributed. Wilcoxon signed rank test was used for within-group difference from 0 for the change at 4 and 7 months in control group. P value <.025 was
used for significance to account for the Bonferroni correction of multiple comparisons. One-way ANOVA compared between-group difference of means at 4 and 7
months; P value <.05 used for significance.
e Posthoc t test in a repeated measures ANOVA model to compare within-group change from baseline to 4 and 7 months. P <.025 was used for statistical signific-
ance to account for the Bonferroni correction of multiple comparisons.
f Variables were modeled on the logarithmic scale, and P values are for transformed data. Summary statistics are the original scale for data reporting.
(continued on next page)
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Table 2. Changes in Anthropometric, Clinical, Dietary, and Physical Activity Outcomes of Participants in a Diabetes Prevention
Study at a University Worksite, by Treatment Group at Baseline, 4 Months, and 7 Months, 2012–2014
Outcome
ANOVA Model Effects
Timea
Intervention, Mean (SE)
(n = 35)b
Control, Mean
(SE) (n = 34)b P ValuecTime Group Group × Time
Total cholesterol, mg/dL .01 .42 .06
Baseline 194.7 (4.7) 197.8 (4.8) .64
4 Months −11.3 (4.4) −1.6 (4.4) .12
P value .01 .72 —
7 Months 5.7 (4.4) 0.4 (4.5) .40
P value .19 .92 —
LDL cholesterol, mg/dL .08 .34 .21
Baseline 112.6 (4.1) 114.5 (4.2) .75
4 Months −9.1 (4.2) −0.2 (4.2) .13
P value .03 .96 —
7 Months 2.1 (4.0) 1.6 (4.2) .93
P value .61 .71 —
HDL cholesterol, mg/dL .06 .40 .06
Baseline 50.9 (2.5) 50.5 (2.5) .71f
4 Months −0.04 (1.4) −0.3 (1.4) .95f
P value .67 .76 —
7 Months 4.1 (1.4) −0.3 (1.4) .04f
P value .002 .92 —
Triglycerides, mg/dL .24 .98 .99
Baseline 166.1 (13.1) 163.0 (13.4) .99f
4 Months −8.0 (9.3) −4.8 (9.3) .92f
P value .24 .31 —
7 Months −12.9 (9.1) −3.0 (9.4) .98f
P value .34 .34 —
Systolic blood pressure,
mm Hg .02 .85 .02
Baseline 128.8 (2.4) 124.4 (2.4) .21
4 Months −8.3 (2.2) −0.4 (2.2) .01
P value <.001 .86 —
7 Months −6.3 (2.1) 0.4 (2.2) .03
P value .004 .85 —
Abbreviations: ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a Analyses conducted at baseline, change from baseline to postintervention (4 months), and change from baseline to 3-month follow-up (7 months).
b One participant in intervention group did not complete 4-month data collection, and 1 participant in control group did not complete 7-month data collection.
c Posthoc t test in a repeated measures ANOVA model for between-group comparison at baseline and to compare between-group change from baseline to 4 and 7
months; P value <.05 was used for significance.
d Analyses for primary outcome included student t test for within-group difference from 0 for the change at 4 and 7 months in intervention group; data were not
normally distributed. Wilcoxon signed rank test was used for within-group difference from 0 for the change at 4 and 7 months in control group. P value <.025 was
used for significance to account for the Bonferroni correction of multiple comparisons. One-way ANOVA compared between-group difference of means at 4 and 7
months; P value <.05 used for significance.
e Posthoc t test in a repeated measures ANOVA model to compare within-group change from baseline to 4 and 7 months. P <.025 was used for statistical signific-
ance to account for the Bonferroni correction of multiple comparisons.
f Variables were modeled on the logarithmic scale, and P values are for transformed data. Summary statistics are the original scale for data reporting.
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(continued)
Table 2. Changes in Anthropometric, Clinical, Dietary, and Physical Activity Outcomes of Participants in a Diabetes Prevention
Study at a University Worksite, by Treatment Group at Baseline, 4 Months, and 7 Months, 2012–2014
Outcome
ANOVA Model Effects
Timea
Intervention, Mean (SE)
(n = 35)b
Control, Mean
(SE) (n = 34)b P ValuecTime Group Group × Time
Diastolic blood pressure,
mm Hg <.001 .95 <.001
Baseline 90.9 (1.6) 86.2 (1.6) .04
4 Months −8.5 (1.2) −1.8 (1.3) <.001
P value <.001 .16 —
7 Months −7.5 (1.2) −0.6 (1.3) <.001
P value <.001 .64 —
Total energy, kcal <.001 .10 .13
Baseline 1,797 (117) 1,903 (120) .26f
4 Months −424 (99) −183 (101) .12f
P value <.001 .13 —
7 Months −318 (97) −309 (100) .73f
P value .002 <.001 —
Protein, % of total energy .56 .73 .11
Baseline 15.8 (0.4) 14.9 (0.4) .13
4 Months −0.3 (0.4) 1.0 (0.4) .05
P value .50 .03 —
7 Months −0.3 (0.4) 0.7 (0.4) .12
P value .49 .13 —
Fat, % of energy .30 .14 .007
Baseline 36.7 (1.0) 37.6 (1.1) .54
4 Months −2.6 (0.8) 0.8 (0.9) .008
P value .003 .39 —
7 Months −0.1 (0.8) −0.2 (0.9) .88
P value .94 .78 —
Saturated fat, g/1,000
kcal .02 .09 .006
Baseline 12.6 (0.5) 13.3 (0.5) .32
4 Months −1.5 (0.4) −0.1 (0.4) .01
P value <.001 .79 —
7 Months −0.3 (0.4) −0.6 (0.4) .57
P value .41 .11 —
Abbreviations: ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a Analyses conducted at baseline, change from baseline to postintervention (4 months), and change from baseline to 3-month follow-up (7 months).
b One participant in intervention group did not complete 4-month data collection, and 1 participant in control group did not complete 7-month data collection.
c Posthoc t test in a repeated measures ANOVA model for between-group comparison at baseline and to compare between-group change from baseline to 4 and 7
months; P value <.05 was used for significance.
d Analyses for primary outcome included student t test for within-group difference from 0 for the change at 4 and 7 months in intervention group; data were not
normally distributed. Wilcoxon signed rank test was used for within-group difference from 0 for the change at 4 and 7 months in control group. P value <.025 was
used for significance to account for the Bonferroni correction of multiple comparisons. One-way ANOVA compared between-group difference of means at 4 and 7
months; P value <.05 used for significance.
e Posthoc t test in a repeated measures ANOVA model to compare within-group change from baseline to 4 and 7 months. P <.025 was used for statistical signific-
ance to account for the Bonferroni correction of multiple comparisons.
f Variables were modeled on the logarithmic scale, and P values are for transformed data. Summary statistics are the original scale for data reporting.
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Table 2. Changes in Anthropometric, Clinical, Dietary, and Physical Activity Outcomes of Participants in a Diabetes Prevention
Study at a University Worksite, by Treatment Group at Baseline, 4 Months, and 7 Months, 2012–2014
Outcome
ANOVA Model Effects
Timea
Intervention, Mean (SE)
(n = 35)b
Control, Mean
(SE) (n = 34)b P ValuecTime Group Group × Time
Trans fat, g/1,000 kcal .02 .11 .30
Baseline 1.3 (0.1) 1.4 (0.1) .48
4 Months −0.2 (0.1) −0.05 (0.1) .13
P value .003 .42 —
7 Months −0.1 (0.06) −0.1 (0.1) .53
P value .04 .26 —
Monounsaturated fat, g/
1,000 kcal .63 .19 .03
Baseline 16.2 (0.5) 16.5 (0.5) .67
4 Months −1.0 (0.5) 0.6 (0.5) .02
P value .05 .19 —
7 Months 0.2 (0.5) 0.2 (0.5) .97
P value .73 .69 —
Polyunsaturated fat, g/
1,000 kcal .48 .70 .53
Baseline 8.9 (0.3) 8.8 (0.3) .89
4 Months −0.17 (0.3) 0.3 (0.3) .27
P value .59 .32 —
7 Months 0.2 (0.3) 0.3 (0.3) .75
P value .54 .30 —
Carbohydrate, % of total
energy .14 .31 .002
Baseline 46.7 (1.3) 46.8 (1.3) .96
4 Months 3.7 (1.0) −1.0 (1.0) <.001
P value <.001 .30 —
7 Months 0.6 (1.0) −0.04 (1.0) .62
P value .51 .96 —
Fiber, g/1,000 kcal <.001 .50 .06
Baseline 10.5 (0.6) 10.0 (0.6) .87f
4 Months 2.2 (0.5) 0.9 (0.5) .05f
P value <.001 .06 —
7 Months 0.8 (0.4) 1.2 (0.5) .87f
P value .02 .02 —
Abbreviations: ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a Analyses conducted at baseline, change from baseline to postintervention (4 months), and change from baseline to 3-month follow-up (7 months).
b One participant in intervention group did not complete 4-month data collection, and 1 participant in control group did not complete 7-month data collection.
c Posthoc t test in a repeated measures ANOVA model for between-group comparison at baseline and to compare between-group change from baseline to 4 and 7
months; P value <.05 was used for significance.
d Analyses for primary outcome included student t test for within-group difference from 0 for the change at 4 and 7 months in intervention group; data were not
normally distributed. Wilcoxon signed rank test was used for within-group difference from 0 for the change at 4 and 7 months in control group. P value <.025 was
used for significance to account for the Bonferroni correction of multiple comparisons. One-way ANOVA compared between-group difference of means at 4 and 7
months; P value <.05 used for significance.
e Posthoc t test in a repeated measures ANOVA model to compare within-group change from baseline to 4 and 7 months. P <.025 was used for statistical signific-
ance to account for the Bonferroni correction of multiple comparisons.
f Variables were modeled on the logarithmic scale, and P values are for transformed data. Summary statistics are the original scale for data reporting.
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(continued)
Table 2. Changes in Anthropometric, Clinical, Dietary, and Physical Activity Outcomes of Participants in a Diabetes Prevention
Study at a University Worksite, by Treatment Group at Baseline, 4 Months, and 7 Months, 2012–2014
Outcome
ANOVA Model Effects
Timea
Intervention, Mean (SE)
(n = 35)b
Control, Mean
(SE) (n = 34)b P ValuecTime Group Group × Time
Total sugars, g/1,000
kcal .47 .34 .06
Baseline 51.6 (2.8) 52.5 (2.9) .84
4 Months 6.8 (2.8) −2.4 (2.8) .02
P value .02 .39 —
7 Months 3.6 (2.7) 0.4 (2.8) .41
P value .19 .90 —
Moderate/vigorous
intensity physical activity,
total minutes per week
.34 .28 .20
Baseline 122.6 (14.8) 106.9 (15.3) .80f
4 Months 23.9 (12.0) 2.2 (12.4) .08f
P value .02 .83 —
7 Months 6.8 (11.9) 9.9 (12.2) .29f
P value .20 .80 —
Abbreviations: ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a Analyses conducted at baseline, change from baseline to postintervention (4 months), and change from baseline to 3-month follow-up (7 months).
b One participant in intervention group did not complete 4-month data collection, and 1 participant in control group did not complete 7-month data collection.
c Posthoc t test in a repeated measures ANOVA model for between-group comparison at baseline and to compare between-group change from baseline to 4 and 7
months; P value <.05 was used for significance.
d Analyses for primary outcome included student t test for within-group difference from 0 for the change at 4 and 7 months in intervention group; data were not
normally distributed. Wilcoxon signed rank test was used for within-group difference from 0 for the change at 4 and 7 months in control group. P value <.025 was
used for significance to account for the Bonferroni correction of multiple comparisons. One-way ANOVA compared between-group difference of means at 4 and 7
months; P value <.05 used for significance.
e Posthoc t test in a repeated measures ANOVA model to compare within-group change from baseline to 4 and 7 months. P <.025 was used for statistical signific-
ance to account for the Bonferroni correction of multiple comparisons.
f Variables were modeled on the logarithmic scale, and P values are for transformed data. Summary statistics are the original scale for data reporting.
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Table 3. Attainment of Program Goals Among Intervention and Control Participants in a Diabetes Prevention Study at a University
Worksite, by Treatment Group at Baseline, 4 Months, and 7 Months, 2012–2014a
Program Goal
Baseline 4 Months (Postintervention) 7 Months (3-Month Follow-Up)
Intervention (n
= 35)
Control (n
= 34) P
b Intervention (n
= 34)c
Control (n
= 34)c P
b Intervention (n
= 35)
Control (n
= 33) P
b
>5% Weight loss — — — 18 (52.9) 1 (2.9)
<.001
17 (48.6) 3 (9.1)
<.0010%–5% Weightloss
— — — 14 (41.2) 17 (50.0) 13 (37.1) 12 (36.4)
Weight gain — — — 2 (5.9) 16 (47.1) 5 (14.3) 18 (54.5)
150 Min/wk
MVPA
10 (28.6) 8 (23.5) .79d 17 (50.0) 8 (25.0) .05d 12 (34.3) 9 (27.3) .60d
<30% Energy
from fat
3 (8.6) 2 (5.9)
.87
13 (39.4) 3 (9.4)
.01
6 (17.1) 1 (3.0)
.1330%–35% Energyfrom fat
8 (22.9) 7 (20.6) 6 (18.2) 5 (15.6) 6 (17.1) 9 (27.3)
>35% Energy
from fat
24 (68.6) 25 (73.5) 14 (42.4) 24 (75.0) 23 (65.7) 23 (69.7)
Abbreviations: MVPA, moderate to vigorous intensity physical activity.
a Values are number (percentage) unless otherwise indicated
b Pearson χ2 test of between-group differences in proportions; P value <.05 was used for significance.
c One participant in intervention and 2 in control group did not complete dietary questionnaire postintervention; 2 participants were missing accelerometer data in
the control group postintervention.
d Fisher exact test of between-group differences in proportions; P value <.05 was used for significance.
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